Helichrysetin and TNF‑α synergistically promote apoptosis by inhibiting overactivation of the NF‑κB and EGFR signaling pathways in HeLa and T98G cells

Int J Mol Med. 2021 Apr;47(4):49. doi: 10.3892/ijmm.2021.4882. Epub 2021 Feb 12.

Abstract

Tumor necrosis factor‑α (TNF‑α) has different effects on apoptosis depending on activation or inactivation of the nuclear factor‑κB (NF‑κB) and epidermal growth factor receptor (EGFR) signaling pathways. Helichrysetin, a natural chalcone, inhibits NF‑κB nuclear translocation in mouse pancreatic β cells. The present study aimed to identify the effect of helichrysetin on activation of the NF‑κB and EGFR signaling pathways induced by TNF‑α, and the synergistic effect of helichrysetin and TNF‑α on apoptosis of HeLa and T98G cells. Cell proliferation was measured by Cell Counting Kit‑8 assay, while apoptosis was measured by Hoechst 33258 and Annexin V/PI staining. NF‑κB activity was detected by luciferase assay, protein expression was measured by western blotting and mRNA expression was detected by quantitative PCR assay. The results revealed that in HeLa and T98G cells helichrysetin blocked the increased phosphorylation of NF‑κB p65 induced by TNF‑α. Although helichrysetin alone decreased cell viability, helichrysetin and TNF‑α synergistically decreased cell viability. Helichrysetin, not TNF‑α, promoted apoptosis, while the combination of helichrysetin and TNF‑α synergistically increased apoptosis. In addition, helichrysetin and TNF‑α synergistically enhanced the activation of caspase‑3 and poly‑(ADP‑ribose)‑polymerase compared with helichrysetin alone. Helichrysetin inhibited the phosphorylation of transforming growth factor‑β activated kinase (TAK1), IκB kinase‑α/β (IKK‑α/β), NF‑κB p65 and EGFR induced by TNF‑α. Consistent with the inhibition of NF‑κB activation, the increased TNF‑α‑induced mRNA expression levels of TNF‑α, IL‑1β, CCL2, CCL5 and CXCL10 were significantly downregulated by helichrysetin. Therefore, helichrysetin and TNF‑α synergistically promoted apoptosis by inhibiting TAK1/IKK/NF‑κB and TAK1/EGFR signaling pathways in HeLa and T98G cells, indicating a potential therapeutic strategy for cancer.

Keywords: helichrysetin; cancer; TNF‑α; NF‑κB; EGFR; apoptosis.

MeSH terms

  • Apoptosis / drug effects
  • Chalcone / analogs & derivatives*
  • Chalcone / pharmacology
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Chemokine CCL5 / genetics
  • Chemokine CCL5 / metabolism
  • Chemokine CXCL10 / genetics
  • Chemokine CXCL10 / metabolism
  • ErbB Receptors / metabolism
  • HeLa Cells
  • Humans
  • Interleukin-1beta / genetics
  • Interleukin-1beta / metabolism
  • NF-kappa B / metabolism*
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • CCL2 protein, human
  • Chemokine CCL2
  • Chemokine CCL5
  • Chemokine CXCL10
  • IL1B protein, human
  • Interleukin-1beta
  • NF-kappa B
  • Tumor Necrosis Factor-alpha
  • Chalcone
  • helichrysetin
  • EGFR protein, human
  • ErbB Receptors

Grants and funding

This study was supported by the National Natural Science Foundation of China (grant no. 81603156), the Educational Commission of Shanghai of China (grant no. 2020LK014), the Young Eastern Scholar Program (grant no. QD2016038), the Chenguang Program (grant no. 16CG49) and the Graduate Student Innovation Ability Project of Shanghai University of Traditional Chinese Medicine (grant no. Y2020030).